Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Mark A Wainberg"'
Publikováno v:
Infection, Genetics and Evolution. 46:286-291
Three integrase strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), have been approved by the FDA. Resistance against these three INSTIs have been reported and cross-resistance among them has been docume
Autor:
Shan Cen, Qinghua Pan, Zhen Wang, Chen Liang, Fei Guo, Mark A. Wainberg, Weijun Zhu, Patrick Gendron
Publikováno v:
Cell Reports, Vol 15, Iss 3, Pp 481-489 (2016)
SummaryCas9 cleaves specific DNA sequences with the assistance of a programmable single guide RNA (sgRNA). Repairing this broken DNA by the cell’s error-prone non-homologous end joining (NHEJ) machinery leads to insertions and deletions (indels) th
Autor:
Mark A. Wainberg, Thibault Mesplède
Publikováno v:
Viruses
Viruses, Vol 7, Iss 7, Pp 3703-3718 (2015)
Viruses, Vol 7, Iss 7, Pp 3703-3718 (2015)
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem
Publikováno v:
Journal of Virology. 89:4681-4684
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections w
Autor:
Tamar Veres, Maureen Oliviera, Said Hassounah, Yolanda Lie, Wei Huang, Ying-Shan Han, Mark A. Wainberg, Peter K. Quashie, Thibault Mesplède, Nathan Osman
Publikováno v:
Journal of Virology. 89:3163-3175
Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a
Autor:
Fred Kyeyune, Ruxandra-Ilinca Ibanescu, Miguel E. Quiñones-Mateu, Michel Roger, Isabelle Hardy, Mark A. Wainberg, Jean-Pierre Routy, Maureen Oliveira, Bluma G. Brenner
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives: Viral phylogenetics revealed two patterns of HIV-1 spread among MSM in Quebec. While most HIV-1 strains (n = 2011) were associated with singleton/small clusters (cluster size 1–4), 30 viral lineages formed large networks (cluster size 2
Autor:
Navaneethan Palanisamy, Frédéric Ohnona, Mark A. Wainberg, Hongtao Xu, Thibault Mesplède, Nathan Osman, Bluma G. Brenner
Publikováno v:
AIDS Research and Therapy
Background Codon usage bias has been described for various organisms and is thought to contribute to the regulation of numerous biological processes including viral infections. HIV-1 codon usage has been previously shown to be different from that of
Autor:
Alonso Heredia, Mohammed N. Amin, Steven G. Deeks, Maureen Oliveira, Robert R. Redfield, Charles B. Davis, Mark A. Wainberg, Lai-Xi Wang, Nhut Le
Publikováno v:
AIDS (London, England), vol 28, iss 3
Objective The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhib
Autor:
Nathan Osman, Thibault Mesplède, Mark A. Wainberg, Katlin Anstett, Jiaming Liang, Hanh T. Pham
Publikováno v:
Journal of Virus Eradication, Vol 2, Iss, Pp 27-(2016)
Publikováno v:
Retrovirology
Retrovirology, 13(1). BioMed Central
Retrovirology, 13(1). BioMed Central
The major barrier to eradication of HIV infection is the latent viral reservoir that persists despite long-term highly active antiretroviral therapy (HAART). The main reason for the existence of latently infected cells is that proviral DNA becomes in